Affymax is a biopharmaceutical company creating novel approaches for the treatment of kidney disease and cancer. It seeks to build a franchise of products through its own internal efforts as well as partnering with other pharmaceutical companies such as Takeda and EntreMed. The company's most advanced product candidate Hematide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA).

Report Highlights
Affymax's product focus is in the development of synthetic peptide-based drug candidates. The company has developed a discovery platform based on advanced recombinant peptide and peptide chemistry techniques that allows it to generate novel peptide alternatives to protein drugs. Affymax derives its revenues from collaboration and licensing agreements. These revenues are related mainly to the two separate collaboration agreements with Takeda for the development and commercialization of Hematide. During the period 2002-2006, the company's total revenues increased from $0.1 million in 2002 to $12 million in 2006. Affymax's major contributor to sales growth out to 2010 will be the royalties, license and collaboration revenues. Revenues from this stream are expected to contribute absolute sales growth of +$100 million during the period 2006-2010. The absolute increase from this revenue stream is expected primarily due to the revenues earned in
[Studien Infos ausblenden]

Table 1: Affymax - Key Facts 7
Table 2: Affymax - Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
Table 3: Affymax - Key Events Impacting Share Price Performance 12
Table 4: Affymax - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
Table 5: Affymax - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
Table 6: Affymax - Balance Sheet, 2002-2006 ($ Mn) 16
Table 7: Affymax - Cash Flow, 2002-2006 ($ Mn) 16
Table 8: Affymax - Revenue Breakdown, 2002-2006 ($ Mn) 17
Table 9: Affymax – In-house Pipeline Products 18
Table 10: Affymax – Collaboration Pipeline Products 19
Table 11: Affymax – Forecast Sales, 2006-2010 ($ Mn) 21
Table 12: Affymax – Top Competitors 23
Table 13: Affymax – Key Suppliers 24
Table 14: Affymax - Key Shareholders 25
Table 15: Affymax - SWOT Analysis Summary 30
Table 16: Affymax – Value Chain Analysis 35
Table 17: Affymax - Scorecard 37
Table 18: Affymax - Key Employees 39
Table 19: Affymax - Financial and Operational Overview 49
Figure 1: Affymax - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
Figure 2: Affymax - Key Strategic Revenues, 2006-2010 ($ Mn) 22
[Tabellenverzeichnis ausblenden]